References:
1. World Health Organization. Coronavirus disease 2019(COVID-19) Situation Report. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200716-covid-19-sitrep-178.pdf?sfvrsn=28ee165b_2
2. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? [published online ahead of print, 2020 May 15]. Lancet Respir Med . 2020;S2213-2600(20)30222-8.
3. Zhang P, Li J, Liu H. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res . 2020;8:8.
4. Das KM, Lee EY, Singh R. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging . 2017;27:342–349.
5. Ballester B, Milara J, Cortijo J. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets. Int J Mol Sci . 2019 Feb; 20(3): 593.
6. Lance L. Munn. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med . 2017 Mar; 9(2): 10.1002/wsbm.1370.
7. O’Callaghan DS, O’Donnell D, O’Connell F, O’Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J THORAC ONCOL . 2010;5(12):2024-36.
8. Xu J, Fan J, Wu F, et al. The ACE2/Angiotensin-(1–7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. FRONT PHYSIOL . 2017;8:276.
9. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus Disease 2019 (COVID 19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? J. Am. Heart Assoc . 2020;9(7):e016509.
10. Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci. Transl. Med . 2017;9(410):eaan5616.